[HTML] springer.comFull View

[HTML][HTML] Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study

S Piva, RM DiBlasi, AE Slee, AH Jobe, AM Roccaro… - Respiratory …, 2021 - Springer
Background COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …
被引用次数：68 相关文章

Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study.

S Piva, RM DiBlasi, AE Slee, AH Jobe… - Respiratory …, 2021 - go.gale.com
Background COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …
[HTML] nih.gov

[HTML][HTML] Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study

S Piva, RM DiBlasi, AE Slee, AH Jobe… - Respiratory …, 2021 - ncbi.nlm.nih.gov
Background COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …
[HTML] europepmc.org

[HTML][HTML] Surfactant Therapy for COVID-19 Related ARDS: A Retrospective Case-Control Pilot Study.

S Piva, D Robert, AE Slee, AH Jobe, AM Roccaro… - 2020 - europepmc.org
Background:. COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …
[HTML] biomedcentral.com

[HTML][HTML] Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study

S Piva, RM DiBlasi, AE Slee… - Respiratory …, 2021 - respiratory-research.biomedcentral …
COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes the lungs of
surfactant, leading to prolonged mechanical ventilation and death. The feasibility and safety …

Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study

S Piva, RM Diblasi, AE Slee, AH Jobe… - RESPIRATORY …, 2021 - iris.unibs.it
Background: COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …

Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study

S Piva, RM DiBlasi, AE Slee, AH Jobe… - Respiratory …, 2021 - pubmed.ncbi.nlm.nih.gov
Background COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …

Surfactant therapy for COVID-19 related ards: a retrospective case-control pilot study.

S Piva, RM Diblasi, AE Slee, AH Jobe, AM Roccaro… - 2021 - cabidigitallibrary.org
Background: COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …
[PDF] archive.org

[PDF][PDF] Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study

S Piva, RM DiBlasi, AE Slee, AH Jobe, AM Roccaro… - 2021 - scholar.archive.org
Background: COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …
[PDF] academia.edu

[PDF][PDF] Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study

S Piva, RM DiBlasi, AE Slee, AH Jobe, AM Roccaro… - 2021 - academia.edu
Background: COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …